Intercept Hopes Statin Trial Will Lessen Ocaliva's Perceived CV Risk

After otherwise successful Phase II NASH trial showed Ocaliva can increase a patient's LDL cholesterol levels, Intercept hopes a study in NASH patients who use atorvastatin will show this effect is manageable.

Liver

Intercept Pharmaceuticals Inc. is hoping that its ongoing Phase II CONTROL study will ameliorate a lingering concern about Ocaliva's prospects in non-alcoholic steatohepatitis (NASH) by showing that co-administration of a statin can manage the LDL-elevating effect seen in some patients receiving the drug.

Ocaliva (obeticholic acid/OCA), a farnesoid X receptor (FXR) agonist already approved in the US and Europe to treat primary biliary...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D